View in EDS

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Saved in:
Bibliographic Details
Title: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Authors: Wu, Yi-Long1 syylwu@live.cn, Cheng, Ying2, Zhou, Xiangdong3, Lee, Ki Hyeong4, Nakagawa, Kazuhiko5, Niho, Seiji6, Tsuji, Fumito7, Linke, Rolf8, Rosell, Rafael9, Corral, Jesus10, Migliorino, Maria Rita11, Pluzanski, Adam12, Sbar, Eric I13, Wang, Tao14, White, Jane Liang14, Nadanaciva, Sashi14, Sandin, Rickard15, Mok, Tony S16
Source: Lancet Oncology. Nov2017, Vol. 18 Issue 11, p1454-1466. 13p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 125982993
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Wu%2C+Yi-Long%22">Wu, Yi-Long</searchLink><relatesTo>1</relatesTo><i> syylwu@live.cn</i><br /><searchLink fieldCode="AR" term="%22Cheng%2C+Ying%22">Cheng, Ying</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Zhou%2C+Xiangdong%22">Zhou, Xiangdong</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Lee%2C+Ki+Hyeong%22">Lee, Ki Hyeong</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Nakagawa%2C+Kazuhiko%22">Nakagawa, Kazuhiko</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Niho%2C+Seiji%22">Niho, Seiji</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Tsuji%2C+Fumito%22">Tsuji, Fumito</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Linke%2C+Rolf%22">Linke, Rolf</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Rosell%2C+Rafael%22">Rosell, Rafael</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Corral%2C+Jesus%22">Corral, Jesus</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Migliorino%2C+Maria+Rita%22">Migliorino, Maria Rita</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Pluzanski%2C+Adam%22">Pluzanski, Adam</searchLink><relatesTo>12</relatesTo><br /><searchLink fieldCode="AR" term="%22Sbar%2C+Eric+I%22">Sbar, Eric I</searchLink><relatesTo>13</relatesTo><br /><searchLink fieldCode="AR" term="%22Wang%2C+Tao%22">Wang, Tao</searchLink><relatesTo>14</relatesTo><br /><searchLink fieldCode="AR" term="%22White%2C+Jane+Liang%22">White, Jane Liang</searchLink><relatesTo>14</relatesTo><br /><searchLink fieldCode="AR" term="%22Nadanaciva%2C+Sashi%22">Nadanaciva, Sashi</searchLink><relatesTo>14</relatesTo><br /><searchLink fieldCode="AR" term="%22Sandin%2C+Rickard%22">Sandin, Rickard</searchLink><relatesTo>15</relatesTo><br /><searchLink fieldCode="AR" term="%22Mok%2C+Tony+S%22">Mok, Tony S</searchLink><relatesTo>16</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet+Oncology%22">Lancet Oncology</searchLink>. Nov2017, Vol. 18 Issue 11, p1454-1466. 13p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=125982993
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(17)30608-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 13
        StartPage: 1454
    Titles:
      – TitleFull: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wu, Yi-Long
      – PersonEntity:
          Name:
            NameFull: Cheng, Ying
      – PersonEntity:
          Name:
            NameFull: Zhou, Xiangdong
      – PersonEntity:
          Name:
            NameFull: Lee, Ki Hyeong
      – PersonEntity:
          Name:
            NameFull: Nakagawa, Kazuhiko
      – PersonEntity:
          Name:
            NameFull: Niho, Seiji
      – PersonEntity:
          Name:
            NameFull: Tsuji, Fumito
      – PersonEntity:
          Name:
            NameFull: Linke, Rolf
      – PersonEntity:
          Name:
            NameFull: Rosell, Rafael
      – PersonEntity:
          Name:
            NameFull: Corral, Jesus
      – PersonEntity:
          Name:
            NameFull: Migliorino, Maria Rita
      – PersonEntity:
          Name:
            NameFull: Pluzanski, Adam
      – PersonEntity:
          Name:
            NameFull: Sbar, Eric I
      – PersonEntity:
          Name:
            NameFull: Wang, Tao
      – PersonEntity:
          Name:
            NameFull: White, Jane Liang
      – PersonEntity:
          Name:
            NameFull: Nadanaciva, Sashi
      – PersonEntity:
          Name:
            NameFull: Sandin, Rickard
      – PersonEntity:
          Name:
            NameFull: Mok, Tony S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2017
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-print
              Value: 14702045
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Lancet Oncology
              Type: main
ResultId 1